The latest news from academia, regulators
research labs and other things of interest
Posted: March 12, 2009
ADMEcell Enters into Agreement with Advancell
(Nanowerk News) ADMEcell, announced that it has entered into an exclusive agreement with Advancell, Barcelona, Spain, to manufacture and distribute the CacoReady™ System for the North American market. The CacoReady™ System is a new, innovative tool designed to optimize the time and costs of evaluating the intestinal absorption of compounds. The kit has been designed to provide a Ready-To-Use user-friendly kit and suitable for high-throughput automated procedures. It provides users with the differentiated Caco-2 barrier (21-day system), plated on 24- or 96-Transwell plates.
“This kit with differentiated Caco-2 cell barriers is an innovation that is being offered in North America for the first time,” says Sandy Koshkin, President of ADMEcell. “Our customers gain considerable savings of both cost and time.” The CacoReady product is shipped in proprietary shipping media at room temperature, and arrives ready for immediate use.
Advancell, Barcelona, Spain, is a leader in nanomedicine and services and reagents in both ADME/Tox and Skin Biology areas, including cell-based assays. Advancell’s business model allows it to achieve reductions in costs, risks and the development time of a drug. Their most successful product to date is the CacoReady™ System. ADVANCELL operates throughout three divisions: Advancell Therapeutics, which is focused on development of new pharmaceutical application of known molecules through innovative testing; Advancell Alternative Testing, which uses in-vitro methods to predict cell efficiency, security, and the mechanism of molecule development, and Advancell Nanosystems, which uses nano-medicine to treat and prevent illnesses. Advancell has three different research centers in Spain.
ADMEcell, Inc. is an on-demand supplier of cell-based assay kits servicing the biotech and life sciences industries. Located in Emeryville, California, the company manufactures and distributes innovative and leading edge products through licensing and distribution agreements. ADMEcell’s product offerings enable rapid, sophisticated cell-based assays designed for in vitro therapeutic modeling and re-profiling. The common theme among the selected technologies is their leading edge nature and prominence within a chosen market.
ADMEcell is currently considering the licensing and/or distribution of unique cell-based assays that have important applications in the drug discovery process. Please contact ADMEcell in confidence if you have a unique, compelling cell-based assay that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology.